Context: Gestational gigantomastia is an uncommon condition characterized by abnormal and excessive growth of breast tissue during an otherwise uncomplicated pregnancy. Gestational gigantomastia may be accompanied by hypercalcemia, which in some cases has been associated with elevated serum levels of PTHrP. The source of the PTHrP in these cases has been suggested to be the enlarged breasts.
14 mg/dL [normal (nl) 8.9 to 10.3], PTH 7.9 pg/mL (nl 14.0 to 72.0), and PTHrP 32 pg/mL (nl 14 to 27); the serum level of 25(OH)D was below the detection limit by immunoassay and the serum level of 1,25(OH) 2 D was 40 pg/mL (first trimester nl 20 to 65). The patient denied ingestion of excessive calcium or vitamin D, and there was no history of hypercalcemia or similar breast enlargement during previous pregnancies. She underwent a breast biopsy, which disclosed only hyperplasia. Whole body magnetic resonance imaging did not reveal evidence of malignancy. Computed tomography of the chest was unremarkable. Biopsy of an enlarged axillary lymph node showed no evidence of malignancy or granulomatous disease. An abdominal ultrasound revealed bilateral nephrolithiasis. Subsequently, she was transferred to the Hospital of the University of Pennsylvania (HUP) at week 17 of gestation for management of hypercalcemia and bilateral mastitis. The initial laboratory evaluation at HUP is presented in Table 1 .
The patient was treated with IV normal saline and prednisone (initially 20 mg orally daily, and uptitrated after 3 days to 30 mg per day) without substantial improvement in serum calcium levels. She was then treated with subcutaneous calcitonin (final dose 560 IU every 6 hours). She was also treated with cinacalcet (30 mg by mouth twice daily, later increased to 60 mg twice daily) as discussed here. Risks and benefits of this medication were discussed with the patient, and she was made aware that this was an off-label use of cinacalcet. Corrected calcium levels improved to the upper limit of normal, but soon increased again due to suspected calcitonin tachyphylaxis. She refused bilateral breast reduction surgery and requested termination of pregnancy, which was performed at week 20 of gestation. There was rapid resolution of hypercalcemia immediately postoperatively: corrected calcium decreased from 12.8 to 10.9 and 9.5 mg/dL on postoperative days 1 and 2, respectively (Fig. 1A) . PTH increased from 0.7 to 2.0 pmol/L and PTHrP decreased from 29.7 to 5.0 and 2.9 pmol/L on postoperative days 1 and 4, respectively (Fig. 1B) . Unfortunately, she was lost to follow-up until 6 months later when she presented for bilateral subcutaneous mastectomy as breast reduction surgery (Fig. 2) . At that time, her preoperative laboratories showed mild hypocalcemia (calcium of 7.7 mg/dL), PTH 6.0 pmol/L, phosphorus 3.6 mg/dL, and severe 25(OH)D deficiency 7 ng/mL, which was subsequently treated with cholecalciferol. Histological analysis of resected breast tissue revealed dense tissue with fibroadenomas, pseudoangiomatous stromal hyperplasia, ectatic vessels, focal apocrine and lactational changes, and areas of infarct. Two months postreduction surgery, biochemical analysis showed normal levels of calcium (9.4 mg/dL), PTH (4.0 pmol/L), and PTHrP (,2.0 pmol/L).
Discussion
Gigantomastia is an uncommon condition that is characterized by abnormal and excessive growth of breast tissue. Diagnostic criteria include excessive breast weight or percentage of total body weight (1), and proposed classifications (2) include idiopathic, hormonal (including pregnancy-associated or "gestational gigantomastia"), and iatrogenic.
Gigantomastia has rarely been associated with hypercalcemia, both in patients who are pregnant (3) (4) (5) and patients who are not pregnant (6) . The combination of gestational gigantomastia and hypercalcemia due to PTHrP has only been reported twice previously. In the first case, a 24-year-old, 24 weeks' gravid female experiencing 2 months of breast enlargement was found to have marked hypercalcemia (3). Hypercalcemia resolved shortly after bilateral mastectomy, and she subsequently delivered a healthy infant at term. Shortly thereafter, PTHrP was discovered and pathological re-examination exhibited immunostaining for PTHrP in the myoepithelial cells surrounding the ducts (7). The second case, recently reported (5), described a 32-year-old, 15 weeks' gravid female who presented with breast enlargement and abdominal pain, and was found to have hypercalcemia with elevated PTHrP. She was treated with bromocriptine, a dopamine agonist, with subsequent arrest in breast enlargement, reductions in PTHrP and, temporarily, serum levels of prolactin, followed subsequently by normalization of serum calcium levels; the patient subsequently delivered a healthy infant at term. Bromocriptine was tapered after delivery without recurrence of hypercalcemia, and the authors hypothesized that breast hypersensitivity to prolactin had led to mammary hyperplasia and excess production of PTHrP from the enlarged breasts. Here, we report the first case of PTHrP-mediated hypercalcemia in gestational gigantomastia with resolution of hypercalcemia and normalization of PTHrP after termination of pregnancy without mastectomy, providing evidence for a placental source of PTHrP.
PTHrP is expressed in a variety of tissues in normal human fetal development (8) . It is produced by the placenta, and is quantitatively less than that seen with malignancy (9) . Concentrations are dynamic but typically increase with advancing gestation (10) with concentrations reported to be 15-fold higher than that of PTH at term. PTHrP plays an important role in fetal calcium homeostasis, modulating placental vascular tone and differentiation of various tissues (11) (12) (13) , and in mice has been demonstrated to be essential for development of the placenta itself (14) . PTHrP release is modulated through interaction with the calcium-sensing receptor (CaSR), generally in an inverse relationship whereby CaSR activation inhibits PTHrP production (15) . However, in malignantly transformed breast cells, a switch in CaSR G-protein preference from Ga i (inhibition of adenylyl cyclase) to Ga s (stimulation of cAMP production) causes CaSR activation to lead to stimulation of PTHrP production (16) . Studies examining PTHrP-mediated hypercalcemia in breast cancer have also shown that CaSR disruption leads to reduced tumor PTHrP expression (17) . CaSR is expressed on normal breast epithelial cells, including during pregnancy, and plays an important role in regulating the balance of systemic calcium metabolism and calcium transport into milk (18, 19) . Previous mouse (20) and human (21) studies have described calcium normalization with cinacalcet in PTHrP-mediated hypercalcemia. CaSR is also present in the placenta (22) . Therefore, we decided to trial cinacalcet, a calcimimetic agent that increases the sensitivity of CaSR to activation by extracellular calcium, with hope that increased CaSR activation would inhibit PTHrP production. This was an off-label use of cinacalcet, and the patient was made aware of the risks and benefits of trialing this medication. Cinacalcet has been approved by the Food and Drug Administration for secondary hyperparathyroidism in patients with chronic kidney disease requiring dialysis, hypercalcemia in patients with parathyroid carcinoma, and severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy. Although the CaSR on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH synthesis and secretion, CaSR is also expressed in multiple other tissues, including the kidneys, bone marrow, osteoclasts, osteoblasts, thyroid C-cells, and gastrin-secreting cells in the stomach, intestine, brain, and breast (23) .
CaSR is present in the placenta (22) and so cinacalcet could theoretically inhibit physiological placental active calcium transport. Cinacalcet crosses the placenta in rabbits, though no teratogenicity was observed at doses less than the human equivalent of 180 mg daily and no teratogenicity was reported in rats at higher doses (up to four times the human equivalent of 180 mg daily) (24) . The drug is classified as pregnancy category C and clinical reports of cinacalcet use in pregnancy are limited. These reports generally describe third-trimester hypercalcemia in patients with primary hyperparathyroidism (25) (26) (27) (28) (29) , including one report that described elevated cord blood calcium compared with maternal serum suggesting that cinacalcet had not disrupted the physiologic maternal-fetal calcium gradient (28) .
As shown in Fig. 1A , there was significant (but temporary) improvement in serum calcium levels, though the patient was concurrently receiving calcitonin and it is difficult to interpret which agent led to the initial improvement.
We have described a rare case of gestational hypercalcemia associated with gigantomastia that combines several pathologies. Gestational gigantomastia in the absence of hypercalcemia has been reported previously (2, 30) , as has PTHrP-mediated hypercalcemia in pregnancy in the absence of gigantomastia (31) . The possible pathophysiology of PTHrP-mediated hypercalcemia in patients who are pregnant is intriguing in part because of the resolution of hypercalcemia with drastically different interventions. In the original 1988 case report, the patient with gigantomastia underwent bilateral mastectomy that resolved the hypercalcemia (3), suggesting either breast source or stimulation of breast tissue. However, in the patient without gigantomastia, delivery (via Caesarean section) resolved the hypercalcemia (31), suggesting either a placental source or placental signaling. Interestingly, Sato (32) reported a case of a patient who developed PTHrP-mediated hypercalcemic crisis after delivery, and postulated that placental PTHrP had "spilled into the systemic circulation."
The recent report of gestational gigantomastia and PTHrP-mediated hypercalcemia treated with bromocriptine, a dopamine agonist, suggests that increased breast hypersensitivity to prolactin may lead to excessive breast growth and subsequent PTHrP overproduction (5) . Though the use of bromocriptine is intriguing, the proposed pathophysiology does not adequately explain why gestational gigantomastia is not always associated with hypercalcemia (2, 30) or how PTHrP-mediated hypercalcemia can occur in the absence of gigantomastia (31). Pasrija and Sharma (30) , for example, reported a 24-year-old, 26 weeks' gravid female who presented with massive progressive breast enlargement without such breast enlargements in her previous pregnancies. She required only supportive care until delivery at week 38, followed by mammoplasty at 6 weeks' postpartum (30) . Our patient developed gigantomastia and hypercalcemia in her eighth pregnancy (and not in prior pregnancies), which argues against prolactin hypersensitivity, as well as other mechanisms such as prolactin receptor mutations (33) . Resolution of hypercalcemia with placental loss (via termination) in the presence of gigantomastia also argues against this mechanism. We additionally do not suspect that the pathophysiology in our case was related to loss-of-function CYP24A1 mutations, which have been rarely reported to lead to unmasked hypercalcemia of pregnancy (34, 35) , given her low 25(OH)D, elevated PTHrP, and lack of hypercalcemia in prior pregnancies.
Another possible mechanism in our case is stimulation of placental 1a-hydroxylase either by human placental lactogen (hPL) or PTHrP. Our patient presented with an "inappropriately" high-normal 1,25(OH) 2 D 142 pg/mL (second trimester nl 72 to 160) when one would expect suppression of 1a-hydroxylase activity from hypercalcemia through downregulation of CYP27B1 expression. It has been shown that 1,25(OH) 2 D stimulates hPL gene expression (36) . hPL has been reported to be a potent stimulator of PTHrP in vitro (37) as well as an important stimulator of mammary cell proliferation during pregnancy (38) and may therefore play a role in the pathogenesis of gigantomastia. Further, although elevated PTHrP is associated with reduced levels of 1,25(OH) 2 D in humoral hypercalcemia of malignancy, in pregnancy rising PTHrP is thought to contribute to elevation of 1,25(OH) 2 D and PTH suppression (39) . Finally, our patient had elevated levels of both 1,25(OH) 2 D and PTHrP, and it is likely that both of these hormones contributed to the hypercalcemia. Given the intimate and reciprocal regulation of these two calciotropic hormones, it is not possible to specify which was more important to the development of hypercalcemia in our patient. Although it may have been informative to have administered either ketoconazole or rifampin to this patient to reduce serum levels of 1,25(OH) 2 D, as both of these agents have been shown to be useful in treating 1,25(OH) 2 D-induced hypercalcemia (40-42), this was not possible under the circumstances of pregnancy and the timing of the termination of pregnancy.
Conclusions
Gestational gigantomastia causes significant physical and psychological distress. In combination with other possible etiologies, this rare case of gestational gigantomastia associated with elevated serum levels of PTHrP and 1,25(OH) 2 D, with resolution of hypercalcemia and PTHrP excess after termination of pregnancy, suggests an underexplored placenta-breast axis mediated by PTHrP, 1,25(OH) 2 D, and/or possibly hPL.
